M
Michelle Bunzel
Researcher at Merck & Co.
Publications - 7
Citations - 298
Michelle Bunzel is an academic researcher from Merck & Co.. The author has contributed to research in topics: Insulin & Blood sugar. The author has an hindex of 5, co-authored 7 publications receiving 217 citations. Previous affiliations of Michelle Bunzel include United States Military Academy & Harvard University.
Papers
More filters
Journal ArticleDOI
Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy
Robert W. Myers,Hong-Ping Guan,Juliann Ehrhart,Aleksandr Petrov,Srinivasa Prahalada,Effie Tozzo,Xiaodong Yang,Marc M. Kurtz,Maria E. Trujillo,Dinko Gonzalez Trotter,Danqing Feng,Shiyao Xu,George J. Eiermann,Marie A. Holahan,Daniel Rubins,Stacey Conarello,Xiaoda Niu,Sandra C. Souza,Corin O. Miller,Jinqi Liu,Ku Lu,Wen Feng,Ying Li,Ronald E. Painter,James A. Milligan,Huaibing He,Franklin Liu,Aimie Ogawa,Douglas Wisniewski,Rory J. Rohm,Liyang Wang,Michelle Bunzel,Ying Qian,Wei Zhu,Hongwu Wang,Bindu Bennet,Lisa LaFranco Scheuch,Guillermo Fernandez,Cai Li,Michael Klimas,Gaochao Zhou,Margaret van Heek,Tesfaye Biftu,Ann E. Weber,David E. Kelley,Nancy A. Thornberry,Mark D. Erion,Daniel M. Kemp,Iyassu K. Sebhat +48 more
TL;DR: MK-8722 is developed, a potent, direct, allosteric activator of all 12 mammalian AMPK complexes that induced robust, durable, insulin-independent glucose uptake and glycogen synthesis, with resultant improvements in glycemia and no evidence of hypoglycemia in rodents and rhesus monkeys.
Journal ArticleDOI
CM-101: Type I Collagen–targeted MR Imaging Probe for Detection of Liver Fibrosis
Christian T. Farrar,Eric M. Gale,Richard Kennan,Ian Ramsay,Ricard Masia,Gunisha Arora,Kailyn Looby,Lan Wei,Jayashree Kalpathy-Cramer,Michelle Bunzel,Michelle Bunzel,Chunlian Zhang,Yonghua Zhu,Taro E. Akiyama,Michael Klimas,Shirly Pinto,Himashinie V. K. Diyabalanage,Kenneth K. Tanabe,Valerie Humblet,Bryan C. Fuchs,Peter Caravan +20 more
TL;DR: CM-101 demonstrated fast blood clearance and whole-body elimination, negligible accumulation of gadolinium in bone or tissue, and robust detection of fibrosis in rat BDL and mouse CCl4 models of liver fibrosis.
Journal ArticleDOI
GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
Michele Pachanski,Melissa Kirkland,Daniel Kosinski,Joel Mane,Boonlert Cheewatrakoolpong,Jiyan Xue,Daphne Szeto,Gail Forrest,Corin O. Miller,Michelle Bunzel,Christopher W. Plummer,Harry R. Chobanian,Michael W. Miller,Sarah Souza,Brande Thomas-Fowlkes,Aimie M. Ogawa,Adam B. Weinglass,Jerry Di Salvo,Xiaoyan Li,Yue Feng,Daniel Tatosian,Andrew D. Howard,Steven L. Colletti,Maria E. Trujillo +23 more
TL;DR: Comparisons of the glucose lowering profile of AgoPAMs suggest these compounds may possess greater glucose control even in the presence of elevated glucagon secretion, an unexpected feature observed with both acute and chronic treatment with AgoPams.
Journal ArticleDOI
GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
Corin O. Miller,Michele Pachanski,Melissa Kirkland,Daniel Kosinski,Joel Mane,Michelle Bunzel,Jin Cao,Sarah Souza,Brande Thomas-Fowlkes,Jerry Di Salvo,Adam B. Weinglass,Xiaoyan Li,Robert W. Myers,Kevin Knagge,Paul E. Carrington,William K. Hagmann,Maria E. Trujillo +16 more
TL;DR: MK-2305 treatment increases glucose stimulated insulin secretion (GSIS), resulting in changes to hepatic substrate handling that improve glucose homeostasis in the diabetic state, and extends the understanding of the underlying mechanisms by which GPR40 partial agonists reduce hyperglycemia.